ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Matinas BioPharma (MTNB)
Matinas BioPharma stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NYSE
$1.83▲ +10.24%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
41%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Matinas BioPharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Matinas BioPharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Matinas BioPharma a 41% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $1.30 and $2.17; in 9 out of 10, between $0.83 and $3.40. Estimated annual volatility is 162%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $2.6M
- 52-week high
- $22.20
- 52-week low
- $1.47
- Revenue (12 months)
- $0.0M
- Return on equity
- -141.2%
- Free cash flow (12 months)
- $-2.4M
- Beta
- 1.70
What this means
ATLAS does not publish a fair value for MTNB right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks MTNB has traded between $1.47 and $22.20. Today it is 91.8% below that high and 24% above its low.
Its beta is 1.70: it tends to move more than the market, both up and down.
About the company
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products using its lipid nanocrystal (LNC) delivery technology.
Want to see everything about Matinas BioPharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Matinas BioPharma do?
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products using its lipid nanocrystal (LNC) delivery technology.
What is the chance MTNB goes up next month?
41%: somewhat worse than a coin flip. In half of the simulated outcomes, MTNB ends the month between $1.30 and $2.17.
How big is Matinas BioPharma and what is its P/E ratio?
Matinas BioPharma's market capitalization is $2.6M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is MTNB?
ATLAS estimates annual volatility at 162%. In a typical month, half of the outcomes end between $1.30 and $2.17.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer